Stockscreener 앱 받기
100.35
1.28%
1.27
시간 외 거래:
100.90
0.55
+0.55%
전일 마감가:
$99.08
열려 있는:
$100
하루 거래량:
852.05K
Relative Volume:
0.79
시가총액:
$4.64B
수익:
-
순이익/손실:
$-63.78M
주가수익비율:
-37.44
EPS:
-2.68
순현금흐름:
$-53.91M
1주 성능:
+6.49%
1개월 성능:
+41.40%
6개월 성능:
+861.21%
1년 성능:
+668.97%
1일 변동 폭
$97.74
$101.36
1주일 범위
$92.10
$103.06
52주 변동 폭
$7.575
$103.06
Celcuity Inc Stock (CELC) Company Profile
명칭
Celcuity Inc
전화
763-392-0767
주소
16305 36TH AVENUE N, MINNEAPOLIS, MN
CELC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
100.35 | 4.58B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | 개시 | Guggenheim | Buy |
| 2025-07-01 | 재개 | Stifel | Buy |
| 2024-07-22 | 개시 | Leerink Partners | Outperform |
| 2024-02-22 | 개시 | Stifel | Buy |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-08 | 개시 | Canaccord Genuity | Buy |
| 2021-09-07 | 개시 | Jefferies | Buy |
| 2021-07-29 | 개시 | Cowen | Outperform |
| 2021-07-27 | 개시 | Needham | Buy |
| 2021-01-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-11 | 재개 | Craig Hallum | Buy |
| 2018-11-20 | 개시 | H.C. Wainwright | Buy |
모두보기
Celcuity Inc 주식(CELC)의 최신 뉴스
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results - The Motley Fool
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results - The Motley Fool
(CELC) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
How Celcuity Inc. stock reacts to job market dataJuly 2025 Macro Moves & Free Community Consensus Stock Picks - BỘ NỘI VỤ
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium - The Manila Times
Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference - The Manila Times
Celcuity Inc. to Participate in 8th Annual Evercore Healthcare Conference with CEO Fireside Chat Scheduled for December 3, 2025 - Quiver Quantitative
Celcuity Inc. (CELC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Jefferies reiterates Buy rating on Celcuity stock ahead of cancer data - Investing.com India
Jefferies reiterates Buy rating on Celcuity stock ahead of cancer data By Investing.com - Investing.com South Africa
What analysts say about Celcuity Inc stockMarket Sentiment Indicators & Learn to Trade Without Fear of Loss - earlytimes.in
Celcuity (CELC)'s Clinical Success and M&A Potential Underpin Wolfe Research's Bullish View - Finviz
Celcuity (CELC)’s Clinical Success and M&A Potential Underpin Wolfe Research’s Bullish View - Insider Monkey
Celcuity (CELC) Price Target Increased by 16.06% to 97.66 - MSN
Celcuity Director Unloads Shares in a Major Stock Sale! - TipRanks
Celcuity Insider Sold Shares Worth $377,255, According to a Recent SEC Filing - MarketScreener
Dir Buller Sells 3,900 ($377.3K) Of Celcuity Inc [CELC] - TradingView
Dir Dalvey Files To Sell 15,000 Of Celcuity Inc [CELC] - TradingView
Celcuity (CELC) Is Up 9.3% After FDA NDA Submission for Gedatolisib in Breast Cancer TherapyHas The Bull Case Changed? - simplywall.st
Why Celcuity Inc. stock is popular among millennials2025 Pullback Review & AI Forecasted Entry/Exit Points - newser.com
Celcuity initiated with an Outperform at Wolfe Research - MSN
Celcuity submits gedatolisib new drug application to the FDA - MSN
Celcuity Inc. (CELC) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Celcuity stock reaches all-time high of 96.56 USD By Investing.com - Investing.com Canada
How institutional buying supports Celcuity Inc. stock2025 Retail Activity & Fast Gain Swing Trade Alerts - newser.com
How currency fluctuations impact Celcuity Inc. stock2025 Momentum Check & Expert Verified Movement Alerts - newser.com
Price action breakdown for Celcuity Inc.July 2025 Snapshot & Free High Accuracy Swing Entry Alerts - newser.com
Wolfe Research Initiates Coverage of Celcuity (CELC) with Outperform Recommendation - MSN
Key resistance and support levels for Celcuity Inc.2025 Price Momentum & Community Driven Trade Alerts - newser.com
Celcuity (CELC) Is Up 7.6% After FDA Accepts Gedatolisib Application for Expedited ReviewWhat's Changed - Yahoo Finance
When is the best time to exit Celcuity Inc.2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
How to track smart money flows in Celcuity Inc.July 2025 Trade Ideas & Safe Capital Growth Plans - newser.com
Celcuity outlines $2.5B–$3B peak revenue potential for gedatolisib amid accelerated launch preparations - MSN
Wolfe Research initiates coverage on Celcuity stock with Outperform rating By Investing.com - Investing.com South Africa
Celcuity downgraded to Neutral from Buy at H.C. Wainwright - MSN
Wolfe Research initiates coverage on Celcuity stock with Outperform rating - Investing.com India
Celcuity Submits NDA for Gedatolisib to FDA - TipRanks
Celcuity Inc Submits NDA for Gedatolisib to FDA - TradingView
Celcuity Submits New Drug Application for Gedatolisib to Treat Breast Cancer - MarketScreener
Celcuity Inc. Submits New Drug Application for Gedatolisib to Treat Advanced Breast Cancer - Quiver Quantitative
Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer - The Manila Times
Celcuity (Nasdaq: CELC) completes FDA NDA for gedatolisib, cutting progression risk by 76% - Stock Titan
Celcuity Shares Fall After HC Wainwright Downgrade - MarketScreener
Celcuity dips as H.C. Wainwright downgrades to 'neutral' - TradingView
Celcuity Analyst No Longer Bullish Despite Breast Cancer Therapy ApplicationCelcuity (NASDAQ:CELC) - Benzinga
HC Wainwright Downgrades Celcuity to Neutral From Buy, Adjusts PT to $94 From $77 - MarketScreener
HC Wainwright Downgrades Celcuity to Neutral From Buy, Price Target is $94 - MarketScreener
Liquidity Mapping Around (CELC) Price Events - news.stocktradersdaily.com
Celcuity Inc (CELC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.76%
2.16%
자본화:
|
볼륨(24시간):